ASX - Delayed Quote AUD

Anagenics Limited (AN1.AX)

0.0090 -0.0010 (-10.00%)
At close: April 26 at 10:26 AM GMT+10
Key Events
Loading Chart for AN1.AX
DELL
  • Previous Close 0.0100
  • Open 0.0090
  • Bid 0.0090 x --
  • Ask 0.0100 x --
  • Day's Range 0.0090 - 0.0090
  • 52 Week Range 0.0090 - 0.0280
  • Volume 5,389
  • Avg. Volume 425,018
  • Market Cap (intraday) 4.152M
  • Beta (5Y Monthly) -1.02
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date Feb 26, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Anagenics Limited operates as a health and beauty tech company in Australia, New Zealand, and internationally. It develops and sells FGF5 inhibitor formulations; over-the-counter (OTC), cosmetic antiaging, and longevity targeting products; and imports and distributes international and local skin care and wellbeing products under the Thalgo, Hydro Peptide, Comfort Zone, Priori, and Inika Organic brand names. The company also develops, manufactures, and markets beauty and wellness brands comprising Uspa and evolis. It offers its products through various channels, including clinics, retail stores, wholesale pharmacy and spa/salons, online ecommerce, and cross border export markets. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.

anagenics.com

--

Full Time Employees

June 30

Fiscal Year Ends

Related News

Performance Overview: AN1.AX

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AN1.AX
52.63%
S&P/ASX 200 [XJO]
0.20%

1-Year Return

AN1.AX
65.38%
S&P/ASX 200 [XJO]
3.55%

3-Year Return

AN1.AX
86.64%
S&P/ASX 200 [XJO]
7.53%

5-Year Return

AN1.AX
95.24%
S&P/ASX 200 [XJO]
18.64%

Compare To: AN1.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AN1.AX

Valuation Measures

Annual
As of 4/27/2024
  • Market Cap

    4.15M

  • Enterprise Value

    3.67M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.30

  • Price/Book (mrq)

    0.58

  • Enterprise Value/Revenue

    0.36

  • Enterprise Value/EBITDA

    -1.76

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -30.99%

  • Return on Assets (ttm)

    -12.95%

  • Return on Equity (ttm)

    -35.76%

  • Revenue (ttm)

    10.2M

  • Net Income Avi to Common (ttm)

    -2.58M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.35M

  • Total Debt/Equity (mrq)

    12.17%

  • Levered Free Cash Flow (ttm)

    -805.83k

Company Insights: AN1.AX

People Also Watch